132 related articles for article (PubMed ID: 21193152)
1. Pitavastatin - pharmacological profile from early phase studies.
Catapano AL
Atheroscler Suppl; 2010 Dec; 11(3):3-7. PubMed ID: 21193152
[TBL] [Abstract][Full Text] [Related]
2. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.
Kajinami K; Takekoshi N; Saito Y
Cardiovasc Drug Rev; 2003; 21(3):199-215. PubMed ID: 12931254
[TBL] [Abstract][Full Text] [Related]
3. Pitavastatin: an overview.
Saito Y
Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
[TBL] [Abstract][Full Text] [Related]
4. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
da Silva PM
Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
[TBL] [Abstract][Full Text] [Related]
5. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
Yee LL; Wright EA
Clin Ther; 2011 Aug; 33(8):1023-42. PubMed ID: 21816477
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet)].
Yamazaki H; Fujino H; Kanazawa M; Tamaki T; Sato F; Suzuki M; Kitahara M
Nihon Yakurigaku Zasshi; 2004 May; 123(5):349-62. PubMed ID: 15118259
[TBL] [Abstract][Full Text] [Related]
7. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?
Corsini A; Ceska R
Curr Med Res Opin; 2011 Aug; 27(8):1551-62. PubMed ID: 21682551
[TBL] [Abstract][Full Text] [Related]
8. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
9. Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia.
Gotto AM; Moon J
Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1079-90. PubMed ID: 20670185
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin.
Hu M; Tomlinson B
Expert Opin Drug Metab Toxicol; 2014 Jan; 10(1):51-65. PubMed ID: 24156555
[TBL] [Abstract][Full Text] [Related]
11. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
Neuvonen PJ; Niemi M; Backman JT
Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259
[TBL] [Abstract][Full Text] [Related]
12. Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Ahmad H; Cheng-Lai A
Cardiol Rev; 2010; 18(5):264-7. PubMed ID: 20699675
[TBL] [Abstract][Full Text] [Related]
13. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase.
Fujino H; Nakai D; Nakagomi R; Saito M; Tokui T; Kojima J
Arzneimittelforschung; 2004; 54(7):382-8. PubMed ID: 15344842
[TBL] [Abstract][Full Text] [Related]
14. Pitavastatin: a new HMG-CoA reductase inhibitor.
Wensel TM; Waldrop BA; Wensel B
Ann Pharmacother; 2010 Mar; 44(3):507-14. PubMed ID: 20179258
[TBL] [Abstract][Full Text] [Related]
15. Pitavastatin.
Mukhtar RY; Reid J; Reckless JP
Int J Clin Pract; 2005 Feb; 59(2):239-52. PubMed ID: 15854203
[TBL] [Abstract][Full Text] [Related]
16. Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans.
Fujino H; Yamada I; Shimada S; Nagao T; Yoneda M
Arzneimittelforschung; 2002; 52(10):745-53. PubMed ID: 12442637
[TBL] [Abstract][Full Text] [Related]
17. Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial data.
Gosho M; Tanahashi M; Hounslow N; Teramoto T
Int J Clin Pharmacol Ther; 2015 Aug; 53(8):635-46. PubMed ID: 26104032
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1α, did not increase the systemic exposure of pitavastatin.
Lee HI; Choi CI; Sa JH; Lee YJ; Bae JW; Jang CG; Lee SY
Int J Clin Pharmacol Ther; 2014 Nov; 52(11):981-5. PubMed ID: 25138679
[TBL] [Abstract][Full Text] [Related]
19. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization.
Fujino H; Yamada I; Shimada S; Yoneda M; Kojima J
Xenobiotica; 2003 Jan; 33(1):27-41. PubMed ID: 12519692
[TBL] [Abstract][Full Text] [Related]
20. Pitavastatin: a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia.
Baker WL; Datta R
Adv Ther; 2011 Jan; 28(1):13-27. PubMed ID: 21170619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
